Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Pittsburgh
National Institutes of Health Clinical Center (CC)
University of Wisconsin, Madison
National Cancer Institute (NCI)